# Rubicon Research (NSE: RUBICON) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/RUBICON · Pivot · prices to 22 Oct 2026

Rubicon Research (NSE: RUBICON) closed at ₹1,408.90 on 22 Oct 2026, down 3.57% on the day. With a market capitalisation of ₹23,956 Cr, it ranks 316th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 92.3× trailing earnings, against a return on equity of 19.1% in FY26. Its 52-week range is ₹570.75 (24 Oct 2025) to ₹1,899.00 (28 Aug 2026); the last close is 25.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹514 Cr (+50.7% year on year) and net profit ₹77 Cr (+111.8%), on a consolidated basis. Promoters held 59.76% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,408.90 |
| Market cap | ₹23,956 Cr |
| P/E (trailing) | 92.3 |
| ROE | 19.1% (FY26) |
| ROCE | 24.3% (FY26) |
| Debt to equity | 0.2 |
| 52-week high | ₹1,899.00 (28 Aug 2026) |
| 52-week low | ₹570.75 (24 Oct 2025) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹514 Cr | +50.7% | ₹77 Cr | +111.8% | ₹4.66 |
| Q3 FY26 | ₹476 Cr | +51.7% | ₹73 Cr | +91.2% | ₹4.46 |
| Q2 FY26 | ₹412 Cr | +39.2% | ₹54 Cr | +56.2% | ₹3.49 |
| Q1 FY26 | ₹352 Cr | +11.3% | ₹43 Cr | +69.3% | ₹2.81 |
| Q4 FY25 | ₹341 Cr | — | ₹36 Cr | — | ₹2.35 |
| Q3 FY25 | ₹313 Cr | — | ₹38 Cr | — | ₹2.50 |
| Q2 FY25 | ₹296 Cr | — | ₹34 Cr | — | ₹2.27 |
| Q1 FY25 | ₹317 Cr | — | ₹26 Cr | — | ₹1.68 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,284 Cr | ₹134 Cr |
| FY24 | ₹854 Cr | ₹91 Cr |
| FY23 | ₹394 Cr | −₹17 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 59.76%
- Foreign institutions: 7.52%
- Domestic institutions: 9.43%
- Non-institutions: 23.30%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | ₹671.30 | ₹28,313 Cr | 111.9 | 18.0% |
| [Piramal Pharma](https://app.pivotnow.in/stock/PPLPHARMA) | ₹194.27 | ₹25,960 Cr | 25 | −4.0% |
| [Neuland Laboratories](https://app.pivotnow.in/stock/NEULANDLAB) | ₹18,855.00 | ₹24,345 Cr | 66.3 | 19.4% |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | ₹6,856.00 | ₹22,404 Cr | 26 | 62.3% |
| [Piramal Phytoca](https://app.pivotnow.in/stock/PIRPHYTO) | — | ₹21,083 Cr | — | — |
| [SAGILITY](https://app.pivotnow.in/stock/SAGILITY) | ₹44.78 | ₹20,790 Cr | 22.6 | 9.6% |

## Questions and answers

### What is the share price of Rubicon Research today?

Rubicon Research (NSE: RUBICON) last closed at ₹1,408.90 on 22 Oct 2026. Its 52-week high is ₹1,899.00 and its 52-week low is ₹570.75.

### What is the market cap of Rubicon Research?

Rubicon Research's market capitalisation is ₹23,956 Cr (₹23,956 Cr) at the 22 Oct 2026 close, ranking 316th among the NSE companies Pivot tracks.

### What is the P/E ratio of Rubicon Research?

Rubicon Research trades at a trailing P/E of 92.3. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.

### What is the ROE and ROCE of Rubicon Research?

Return on equity was 19.1% in FY26 and return on capital employed was 24.3% in FY26 (consolidated figures).

### Is Rubicon Research a debt-free company?

No. Rubicon Research's debt-to-equity ratio was 0.2 in FY26, with total debt of ₹143 Cr.

### What were Rubicon Research's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Rubicon Research reported revenue of ₹514 Cr, +50.7% year on year, and net profit of ₹77 Cr, +111.8% year on year.

### What is the shareholding pattern of Rubicon Research?

As of 30 Jun 2026: promoters 59.76%, foreign institutions 7.52%, domestic institutions 9.43%, non-institutions 23.30%.

### Who are Rubicon Research's competitors?

The listed Pharma & Healthcare companies closest to Rubicon Research by market cap are Krishna Institute of Medical Sciences, Piramal Pharma, Neuland Laboratories, Procter Gamble, Piramal Phytoca and SAGILITY.

### Is Rubicon Research a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Rubicon Research's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RUBICON against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.